AARTI DRUGS LTD.

NSE : AARTIDRUGSBSE : 524348ISIN CODE : INE767A01016Industry : Pharmaceuticals & DrugsHouse : Aarti
BSE433.85-7.25 (-1.64 %)
PREV CLOSE ( ) 441.10
OPEN PRICE ( ) 440.25
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 39558
TODAY'S LOW / HIGH ( )430.00 450.70
52 WK LOW / HIGH ( )332.15 645
NSE434.30-6.5 (-1.47 %)
PREV CLOSE( ) 440.80
OPEN PRICE ( ) 440.80
BID PRICE (QTY) 434.30 (1751)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 461430
TODAY'S LOW / HIGH( ) 431.05 450.50
52 WK LOW / HIGH ( )332.05 645.75
BSE
1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Incorporation Year : 28-09 1984
Management Info
Prakash M Patil - Chairman Rashesh C Gogri - Managing Director
Registered Office

Address Plot No N 198,M I D C,Tarapur Village - Patembhi, Taluka Palghar,
Thane,
Maharashtra-401506

Phone 022-24019025

Email investorrelations@aartidrugs.com

Website www.aartidrugs.com

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE
NEWS
28Aug Aarti Drugs informs about newspaper cl
Aarti Drugs has informed that the Post Buyback Public Announcement in co..
07Jul Aarti Drugs wins Pharmexcil Outstandin
Aarti Drugs has won Pharmexcil Outstanding Exports Award 2021-2022. The..
07Jul Aarti Drugs moves up on the BSE
Aarti Drugs is currently trading at Rs. 473.55, up by 3.25 points or 0.6..
02May Aarti Drugs informs about disclosure
Aarti Drugs has informed that it is not a Large Corporate as per the app..
28Feb Aarti Drugs informs about analyst meet
Pursuant to the provisions of Regulation 30(6) of SEBI (Listing Obligati..
Financials
Rs. in Millions
QTR Dec 23 ANNUAL 23
Net Profit316.2000000000011528.1
Gross Profit 428.700000000001 2048.1
Operating Profit 614.2000000000012846.3
Net Sales 5382.124979.7
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group
Abbott India (BSE)
 26946.00 (0.74%)
M.Cap (Rs. in Cr)57258.37
Sanofi India (BSE)
 8118.25 (2.06%)
M.Cap (Rs. in Cr)18696.83
Dr. Reddy's Lab (BSE)
 6155.15 (1.78%)
M.Cap (Rs. in Cr)102679.14
Divi's Lab (BSE)
 3436.75 (2.14%)
M.Cap (Rs. in Cr)91234.91
Glaxosmithkline Phar (BSE)
 1943.10 (3.26%)
M.Cap (Rs. in Cr)32917.29
Shareholding Pattern
PROMOTERS 57.47%
NON-INSTITUTION 35.17%
MUTUAL FUNDS/UTI 5.18%
FI/BANKS/INSURANCE 0.08%
GOVERNMENT 0%
FII 0%
ATTENTION INVESTORSKYCIPO
Download Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do’s & Don’t’s) in Vernacular Language :
REGISTRATION NOS.

NSE CM-INZ000234235|NSE F& O - INZ000234235, NSE CD-INZ000234235, BSE CM–INZ000234235 |BSE F & O - INZ000234235|BSE CD- INZ000234235 MCX-SX CM-INZ000234235|MCX-SX F & O - INZ000234235|MCX-SX CD-INZ000234235 NSDL - IN-DP-NSDL-319-2009ROC REG - 21-097912,CDSL : IN-DP-242-2016|SEBI-PMS: INP000007100|LEI- 3358007DLCFNHY8J2F96

Filing compliant on SCORES – Easy & quick

  • Register on SCORES portal
  • Mandatory details for filing complaints on SCORES:
    • Name
    • PAN
    • Address
    • Mobile Number
    • E-mail ID
  • Benefits:
    • i.) Effective communication
    • ii.) Speedy redressal of the grievances
INVESTOR PROTECTION

Compliance officer : Apurva Mittal, Tel No: 022-40790035,022-40790024, Mobile No: 9152943075, E-mail ID: compliance@nnmsecurities.com, cdsl@nnmsecurities.com

Investor grievance : support@nnmsecurities.com

"NNM Securities has partnered with TradingView for its charting technology. An investment and trading platform empowering users with global market data and analytical tools like Stock Screener and Economic Calendar."

Copyright © 2021 NNM Securities.com

Advanced Charts Technology Partner: TradingView

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.